{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:42:41Z","timestamp":1790959361920,"version":"4.1.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T00:00:00Z","timestamp":1729641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacol. Rep"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s43440-024-00668-4","type":"journal-article","created":{"date-parts":[[2024,10,23]],"date-time":"2024-10-23T04:01:57Z","timestamp":1729656117000},"page":"274-286","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety of dapagliflozin and empagliflozin in cases with diabetes mellitus or\/and heart failure: a retrospective pharmacovigilance study conducted on the eudravigilance database"],"prefix":"10.1007","volume":"77","author":[{"given":"Annamaria","family":"Mascolo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Zinzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Gaio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donatella","family":"Ruggiero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Scavone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Capuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,23]]},"reference":[{"key":"668_CR1","unstructured":"Padda IS, Mahtani AU, Parmar M. Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors. StatPearls; 2023."},{"key":"668_CR2","doi-asserted-by":"publisher","unstructured":"Mascolo A, Di Napoli R, Balzano N, Cappetta D, Urbanek K, De Angelis A, et al. Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: a brief summary. Front Cardiovasc Med. 2022;9. https:\/\/doi.org\/10.3389\/FCVM.2022.1010693.","DOI":"10.3389\/FCVM.2022.1010693"},{"key":"668_CR3","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1161\/CIRCULATIONAHA.119.040514\/ASSET\/AD02EA12-F99F-4A8E-9650-D5031F60EDB5\/ASSETS\/IMAGES\/LARGE\/2537FIG01.JPG","volume":"139","author":"S Verma","year":"2019","unstructured":"Verma S, Mcmurray JJV. The Serendipitous Story of SGLT2 inhibitors in Heart failure: New insights from DECLARE-TIMI 58. Circulation. 2019;139:2537\u201341. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040514\/ASSET\/AD02EA12-F99F-4A8E-9650-D5031F60EDB5\/ASSETS\/IMAGES\/LARGE\/2537FIG01.JPG.","journal-title":"Circulation"},{"key":"668_CR4","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1007\/S00228-020-03051-3","volume":"77","author":"AO Bamgboye","year":"2021","unstructured":"Bamgboye AO, Oni IO, Collier A. Predisposing factors for the development of diabetic ketoacidosis with lower than anticipated glucose levels in type 2 diabetes patients on SGLT2-inhibitors: a review. Eur J Clin Pharmacol. 2021;77:651\u20137. https:\/\/doi.org\/10.1007\/S00228-020-03051-3.","journal-title":"Eur J Clin Pharmacol"},{"key":"668_CR5","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1056\/NEJMOA1812389\/SUPPL_FILE","volume":"380","author":"SD Wiviott","year":"2019","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380:347\u201357. https:\/\/doi.org\/10.1056\/NEJMOA1812389\/SUPPL_FILE\/NEJMOA1812389_DATA-SHARING.PDF.","journal-title":"N Engl J Med"},{"key":"668_CR6","doi-asserted-by":"publisher","first-page":"166","DOI":"10.3390\/PHARMACY10060166","volume":"10","author":"L Brust-Sisti","year":"2022","unstructured":"Brust-Sisti L, Rudawsky N, Gonzalez J, Brunetti L. The role of sodium-glucose Cotransporter-2 inhibition in Heart failure with preserved ejection fraction. Pharm (Basel Switzerland). 2022;10:166. https:\/\/doi.org\/10.3390\/PHARMACY10060166.","journal-title":"Pharm (Basel Switzerland)"},{"key":"668_CR7","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1093\/EURHEARTJ\/EHAD389","volume":"44","author":"AK Pandey","year":"2023","unstructured":"Pandey AK, Bhatt DL, Pandey A, Marx N, Cosentino F, Pandey A, et al. Mechanisms of benefits of sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction. Eur Heart J. 2023;44:3640\u201351. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAD389.","journal-title":"Eur Heart J"},{"key":"668_CR8","doi-asserted-by":"publisher","first-page":"105836","DOI":"10.1016\/J.PHRS.2021.105836","volume":"172","author":"A Mascolo","year":"2021","unstructured":"Mascolo A, Scavone C, Scisciola L, Chiodini P, Capuano A, Paolisso G. SGLT-2 inhibitors reduce the risk of cerebrovascular\/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies. Pharmacol Res. 2021;172:105836. https:\/\/doi.org\/10.1016\/J.PHRS.2021.105836.","journal-title":"Pharmacol Res"},{"key":"668_CR9","doi-asserted-by":"publisher","unstructured":"Mascolo A, di Mauro G, Cappetta D, De Angelis A, Torella D, Urbanek K, et al. Current and future therapeutic perspective in chronic heart failure. Pharmacol Res. 2022;175. https:\/\/doi.org\/10.1016\/J.PHRS.2021.106035.","DOI":"10.1016\/J.PHRS.2021.106035"},{"key":"668_CR10","doi-asserted-by":"publisher","unstructured":"Theofilis P, Sagris M, Oikonomou E, Antonopoulos AS, Siasos G, Tsioufis K, et al. Pleiotropic effects of SGLT2 inhibitors and heart failure outcomes. Diabetes Res Clin Pract. 2022;188. https:\/\/doi.org\/10.1016\/J.DIABRES.2022.109927.","DOI":"10.1016\/J.DIABRES.2022.109927"},{"key":"668_CR11","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1515\/JOM-2020-0153","volume":"121","author":"DS Nelinson","year":"2021","unstructured":"Nelinson DS, Sosa JM, Chilton RJ. SGLT2 inhibitors: a narrative review of efficacy and safety. J Osteopath Med. 2021;121:229\u201339. https:\/\/doi.org\/10.1515\/JOM-2020-0153.","journal-title":"J Osteopath Med"},{"key":"668_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13098-020-0516-9\/FIGURES\/3","volume":"12","author":"A Nakamura","year":"2020","unstructured":"Nakamura A, Miyoshi H, Kameda H, Yamashita K, Kurihara Y. Impact of sodium-glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria. Diabetol Metab Syndr. 2020;12:1\u20136. https:\/\/doi.org\/10.1186\/S13098-020-0516-9\/FIGURES\/3.","journal-title":"Diabetol Metab Syndr"},{"key":"668_CR13","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1111\/DOM.13648","volume":"21","author":"T Toyama","year":"2019","unstructured":"Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and meta-analysis. Diabetes Obes Metab. 2019;21:1237\u201350. https:\/\/doi.org\/10.1111\/DOM.13648.","journal-title":"Diabetes Obes Metab"},{"key":"668_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.15605\/JAFES.037.02.04","volume":"37","author":"P Ferwani","year":"2022","unstructured":"Ferwani P, Maldar A, Shah N, Chauhan P, Chadha M. Prevalence of bacterial urinary tract infection among patients with type 2 diabetes Mellitus on Sodium-glucose Cotransporter-2 inhibitors: a prospective real-world setting study. J ASEAN Fed Endocr Soc. 2022;37:5. https:\/\/doi.org\/10.15605\/JAFES.037.02.04.","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"668_CR15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.7326\/M19-0085","volume":"170","author":"SJ Bersoff-Matcha","year":"2019","unstructured":"Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier Gangrene Associated with sodium-glucose Cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med. 2019;170:764\u20139. https:\/\/doi.org\/10.7326\/M19-0085.","journal-title":"Ann Intern Med"},{"key":"668_CR16","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1001\/JAMAINTERNMED.2019.2813","volume":"179","author":"CV Dave","year":"2019","unstructured":"Dave CV, Schneeweiss S, Patorno E. Association of Sodium-Glucose Cotransporter 2 inhibitor treatment with risk of hospitalization for Fournier Gangrene among men. JAMA Intern Med. 2019;179:1587\u201390. https:\/\/doi.org\/10.1001\/JAMAINTERNMED.2019.2813.","journal-title":"JAMA Intern Med"},{"key":"668_CR17","unstructured":"FDA. FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes| FDA 2018. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-warns-about-rare-occurrences-serious-infection-genital-area-sglt2-inhibitors-diabetes (accessed January 31, 2024)."},{"key":"668_CR18","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1016\/S0140-6736(22)02074-8","volume":"400","author":"C Baigent","year":"2022","unstructured":"Baigent C, Emberson JR, Haynes R, Herrington WG, Judge P, Landray MJ, et al. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet (London England). 2022;400:1788\u2013801. https:\/\/doi.org\/10.1016\/S0140-6736(22)02074-8.","journal-title":"Lancet (London England)"},{"key":"668_CR19","doi-asserted-by":"publisher","first-page":"82","DOI":"10.36628\/IJHF.2022.0030","volume":"5","author":"KM Talha","year":"2023","unstructured":"Talha KM, Anker SD, Butler J. SGLT-2 inhibitors in Heart failure: a review of current evidence. Int J Hear Fail. 2023;5:82. https:\/\/doi.org\/10.36628\/IJHF.2022.0030.","journal-title":"Int J Hear Fail"},{"key":"668_CR20","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/S40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement. Drug Saf. 2024;47:575\u201384. https:\/\/doi.org\/10.1007\/S40264-024-01421-9.","journal-title":"Drug Saf"},{"key":"668_CR21","unstructured":"EMA. Forxiga| European Medicines Agency. 2017. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/forxiga (accessed February 14, 2024)."},{"key":"668_CR22","unstructured":"EMA. Jardiance| European Medicines Agency. 2019. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/jardiance (accessed February 14, 2024)."},{"key":"668_CR23","doi-asserted-by":"publisher","first-page":"e14268","DOI":"10.7759\/cureus.14268","volume":"13","author":"M Hussain","year":"2021","unstructured":"Hussain M, Elahi A, Iqbal J, Bilal Ghafoor M, Rehman H, Akhtar S. Comparison of Efficacy and Safety Profile of Sodium-glucose Cotransporter-2 inhibitors as Add-On therapy in patients with type 2 diabetes. Cureus. 2021;13:e14268. https:\/\/doi.org\/10.7759\/cureus.14268.","journal-title":"Cureus"},{"key":"668_CR24","doi-asserted-by":"publisher","first-page":"20230090","DOI":"10.1590\/1806-9282.20230090","volume":"69","author":"A Varshney","year":"2023","unstructured":"Varshney A, Rawat R. Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India. Rev Assoc Med Bras. 2023;69:20230090. https:\/\/doi.org\/10.1590\/1806-9282.20230090.","journal-title":"Rev Assoc Med Bras"},{"key":"668_CR25","doi-asserted-by":"publisher","first-page":"109123","DOI":"10.1016\/J.DIABRES.2021.109123","volume":"182","author":"EJ Ku","year":"2021","unstructured":"Ku EJ, Lee DH, Jeon HJ, Oh TK. Long-term effectiveness and safety of quadruple combination therapy with empagliflozin versus dapagliflozin in patients with type 2 diabetes: 3-year prospective observational study. Diabetes Res Clin Pract. 2021;182:109123. https:\/\/doi.org\/10.1016\/J.DIABRES.2021.109123.","journal-title":"Diabetes Res Clin Pract"},{"key":"668_CR26","doi-asserted-by":"publisher","first-page":"1227199","DOI":"10.3389\/FPHAR.2023.1227199\/BIBTEX","volume":"14","author":"H Alnsasra","year":"2023","unstructured":"Alnsasra H, Tsaban G, Solomon A, Khalil F, Aboalhasan E, Azab AN, et al. Dapagliflozin versus empagliflozin in patients with chronic kidney disease. Front Pharmacol. 2023;14:1227199. https:\/\/doi.org\/10.3389\/FPHAR.2023.1227199\/BIBTEX.","journal-title":"Front Pharmacol"},{"key":"668_CR27","doi-asserted-by":"publisher","first-page":"286","DOI":"10.3390\/PH15030286\/S1","volume":"15","author":"G Di Mauro","year":"2022","unstructured":"Di Mauro G, Mascolo A, Gaio M, Rafaniello C, De Angelis A, Berrino L, et al. The reporting frequency of ketoacidosis events with Dapagliflozin from the European spontaneous reporting system: the DAPA-KETO study. Pharmaceuticals. 2022;15:286. https:\/\/doi.org\/10.3390\/PH15030286\/S1.","journal-title":"Pharmaceuticals"},{"key":"668_CR28","doi-asserted-by":"publisher","unstructured":"Mascolo A, Rafaniello C, di Mauro G, Ruggiero D, Campitiello MR, Donniacuo M, et al. Sodium-glucose cotransporter-2 (SGLT2) inhibitors and the reporting of falls and fractures: an European pharmacovigilance analysis. Front Pharmacol. 2023;14. https:\/\/doi.org\/10.3389\/FPHAR.2023.1245642.","DOI":"10.3389\/FPHAR.2023.1245642"},{"key":"668_CR29","doi-asserted-by":"publisher","unstructured":"Ruggiero R, Fraenza F, Scavone C, di Mauro G, Piscitelli R, Mascolo A, et al. Front Pharmacol. 2020;11:529889. Immune Checkpoint Inhibitors and Immune-Related Adverse Drug Reactions: Data From Italian Pharmacovigilance Database. https:\/\/doi.org\/10.3389\/FPHAR.2020.00830\/BIBTEX","DOI":"10.3389\/FPHAR.2020.00830\/BIBTEX"},{"key":"668_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/S00125-023-05891-X","volume":"66","author":"A Kautzky-Willer","year":"2023","unstructured":"Kautzky-Willer A, Leutner M, Harreiter J. Sex differences in type 2 diabetes. Diabetologia. 2023;66:986. https:\/\/doi.org\/10.1007\/S00125-023-05891-X.","journal-title":"Diabetologia"},{"key":"668_CR31","doi-asserted-by":"publisher","unstructured":"Raschi E, Parisotto M, Forcesi E, La Placa M, Marchesini G, De Ponti F, et al. Adverse events with sodium-glucose co-transporter-2 inhibitors: a global analysis of international spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2017;27:1098\u2013107. https:\/\/doi.org\/10.1016\/J.NUMECD.2017.10.008.","DOI":"10.1016\/J.NUMECD.2017.10.008"},{"key":"668_CR32","unstructured":"PRAC. SGLT2 inhibitors. PRAC makes recommendations to minimise risk of diabetic ketoacidosis| European Medicines Agency 2016. https:\/\/www.ema.europa.eu\/en\/news\/sglt2-inhibitors-prac-makes-recommendations-minimise-risk-diabetic-ketoacidosis (accessed November 3, 2021)."},{"key":"668_CR33","doi-asserted-by":"publisher","first-page":"e2886","DOI":"10.1002\/DMRR.2886","volume":"33","author":"H Qiu","year":"2017","unstructured":"Qiu H, Novikov A, Volker V,|, Vallon V, Diego S, San VA. Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017;33:e2886. https:\/\/doi.org\/10.1002\/DMRR.2886.","journal-title":"Diabetes Metab Res Rev"},{"key":"668_CR34","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12997\/JLA.2022.11.1.1","volume":"11","author":"H Saucedo-Orozco","year":"2022","unstructured":"Saucedo-Orozco H, Voorrips SN, de Boer RA, Westenbrink BD, Yurista SR. SGLT2 inhibitors and Ketone Metabolism in Heart failure. J Lipid Atheroscler. 2022;11:1. https:\/\/doi.org\/10.12997\/JLA.2022.11.1.1.","journal-title":"J Lipid Atheroscler"},{"key":"668_CR35","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1001\/ARCHINTE.164.17.1925","volume":"164","author":"CA Newton","year":"2004","unstructured":"Newton CA, Raskin P. Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med. 2004;164:1925\u201331. https:\/\/doi.org\/10.1001\/ARCHINTE.164.17.1925.","journal-title":"Arch Intern Med"},{"key":"668_CR36","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1210\/JC.2015-1884","volume":"100","author":"SI Taylor","year":"2015","unstructured":"Taylor SI, Blau JE, Rother KI. SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab. 2015;100:2849\u201352. https:\/\/doi.org\/10.1210\/JC.2015-1884.","journal-title":"J Clin Endocrinol Metab"},{"key":"668_CR37","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMOA1911303","volume":"381","author":"JJV McMurray","year":"2019","unstructured":"McMurray JJV, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381:1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMOA1911303.","journal-title":"N Engl J Med"},{"key":"668_CR38","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1136\/HEARTJNL-2020-318060","volume":"107","author":"SS Joshi","year":"2021","unstructured":"Joshi SS, Singh T, Newby DE, Singh J. Sodium-glucose co-transporter 2 inhibitor therapy: mechanisms of action in heart failure. Heart. 2021;107:1032. https:\/\/doi.org\/10.1136\/HEARTJNL-2020-318060.","journal-title":"Heart"},{"key":"668_CR39","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJMOA2022190","volume":"383","author":"M Packer","year":"2020","unstructured":"Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383:1413\u201324. https:\/\/doi.org\/10.1056\/NEJMOA2022190.","journal-title":"N Engl J Med"},{"key":"668_CR40","doi-asserted-by":"publisher","unstructured":"Adamou A, \u00b7 David, Chlorogiannis, IG Kyriakoulis D, Stamatiou I, Koukousaki D, et al. Sodium\u2013glucose cotransporter-2 inhibitors in heart failure patients across the range of body mass index: a systematic review and meta-analysis of randomized controlled trials. Intern Emerg Med. 2024;2024(1\u20139). https:\/\/doi.org\/10.1007\/S11739-024-03532-8.","DOI":"10.1007\/S11739-024-03532-8"},{"key":"668_CR41","doi-asserted-by":"publisher","first-page":"143","DOI":"10.4103\/JFMPC.JFMPC_1349_20","volume":"10","author":"M AlShahrani","year":"2021","unstructured":"AlShahrani M. Prevalence of obesity and overweight among type 2 diabetic patients in Bisha, Saudi Arabia. J Fam Med Prim Care. 2021;10:143. https:\/\/doi.org\/10.4103\/JFMPC.JFMPC_1349_20.","journal-title":"J Fam Med Prim Care"},{"key":"668_CR42","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/EJHF.2728","volume":"25","author":"SD Anker","year":"2023","unstructured":"Anker SD, Khan MS, Butler J, Ofstad AP, Peil B, Pfarr E, et al. Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced. Eur J Heart Fail. 2023;25:117. https:\/\/doi.org\/10.1002\/EJHF.2728.","journal-title":"Eur J Heart Fail"},{"key":"668_CR43","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/1756287215584740\/ASSET\/IMAGES\/LARGE\/10.1177_1756287215584740-FIG8.JPEG","volume":"7","author":"A Chennamsetty","year":"2015","unstructured":"Chennamsetty A, Khourdaji I, Burks F, Killinger KA. Contemporary diagnosis and management of Fournier\u2019s gangrene. Ther Adv Urol. 2015;7:203\u201315. https:\/\/doi.org\/10.1177\/1756287215584740\/ASSET\/IMAGES\/LARGE\/10.1177_1756287215584740-FIG8.JPEG.","journal-title":"Ther Adv Urol"},{"key":"668_CR44","doi-asserted-by":"publisher","unstructured":"Ahmed AE, Abdelkarim S, Zenida M, Baiti MAH, Alhazmi AAY, Alfaifi BAH, et al. Prevalence and Associated Risk factors of urinary tract infection among Diabetic patients: a cross-sectional study. Healthc (Basel Switzerland). 2023;11. https:\/\/doi.org\/10.3390\/HEALTHCARE11060861.","DOI":"10.3390\/HEALTHCARE11060861"},{"key":"668_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-34028-8","volume":"131","author":"CY Chen","year":"2023","unstructured":"Chen CY, Lee CH, Lin HW, Lin SH, Li YH. Impact of infection-related admission in patients with heart failure: a 10 years national cohort study. Sci Rep 2023. 2023;131:13:1\u201310. https:\/\/doi.org\/10.1038\/s41598-023-34028-8.","journal-title":"Sci Rep 2023"},{"key":"668_CR46","doi-asserted-by":"publisher","first-page":"371","DOI":"10.5935\/ABC.20180067","volume":"110","author":"ET Mesquita","year":"2018","unstructured":"Mesquita ET. Infections in heart failure - impact on Mortality. Arq Bras Cardiol. 2018;110:371. https:\/\/doi.org\/10.5935\/ABC.20180067.","journal-title":"Arq Bras Cardiol"},{"key":"668_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2147\/DMSO.S51792","volume":"8","author":"O Nitzan","year":"2015","unstructured":"Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infections in patients with type 2 diabetes mellitus: review of prevalence, diagnosis, and management. Diabetes Metab Syndr Obes. 2015;8:129\u201336. https:\/\/doi.org\/10.2147\/DMSO.S51792.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"668_CR48","doi-asserted-by":"publisher","first-page":"i20","DOI":"10.1093\/IJE\/DYV097.062","volume":"44","author":"K Pouwels","year":"2015","unstructured":"Pouwels K, Bos J, Hak E. ACE-Inhibitors and the risk of urinary tract infections: comparison of a prescription sequence symmetry and a case-crossover design (the Netherlands). Int J Epidemiol. 2015;44:i20\u201320. https:\/\/doi.org\/10.1093\/IJE\/DYV097.062.","journal-title":"Int J Epidemiol"},{"key":"668_CR49","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/S40264-013-0085-Z","volume":"36","author":"KB Pouwels","year":"2013","unstructured":"Pouwels KB, Visser ST, Bos HJ, Hak E. Angiotensin-converting enzyme inhibitor treatment and the development of urinary tract infections: a prescription sequence symmetry analysis. Drug Saf. 2013;36:1079\u201386. https:\/\/doi.org\/10.1007\/S40264-013-0085-Z.","journal-title":"Drug Saf"},{"key":"668_CR50","doi-asserted-by":"publisher","unstructured":"Dobrek L. Lower urinary Tract disorders as adverse drug Reactions\u2014A Literature Review. Pharmaceuticals. 2023;16. https:\/\/doi.org\/10.3390\/PH16071031.","DOI":"10.3390\/PH16071031"},{"key":"668_CR51","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/S40266-013-0145-1","volume":"31","author":"C Tannenbaum","year":"2014","unstructured":"Tannenbaum C, Johnell K. Managing therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinence. Drugs Aging. 2014;31:93. https:\/\/doi.org\/10.1007\/S40266-013-0145-1.","journal-title":"Drugs Aging"},{"key":"668_CR52","doi-asserted-by":"publisher","unstructured":"Dobrek \u0141, DRUG-RELATED URINARY TRACT INFECTIONS. Wiad Lek. 2021;74:1728\u201336. https:\/\/doi.org\/10.36740\/wlek202107130.","DOI":"10.36740\/wlek202107130"}],"container-title":["Pharmacological Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00668-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43440-024-00668-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43440-024-00668-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T01:18:23Z","timestamp":1737335903000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43440-024-00668-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,23]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["668"],"URL":"https:\/\/doi.org\/10.1007\/s43440-024-00668-4","relation":{},"ISSN":["1734-1140","2299-5684"],"issn-type":[{"value":"1734-1140","type":"print"},{"value":"2299-5684","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,23]]},"assertion":[{"value":"17 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"is Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"is Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}